A kill switch for epilepsy? China cuts seizures by 92.6% in first human chemogenetic trial

A groundbreaking clinical trial in China has achieved a remarkable 92.6% reduction in seizures for three patients with refractory epilepsy, marking the first-in-human use of a "molecular switch" in neurology. The innovative approach, known as chemogenetic neuromodulation, involves genetically engineering neurons to express an artificial receptor called hM4D, which can be activated by a low-dose oral drug, clozapine.

This targeted activation effectively "shuts off" abnormal electrical discharges in the brain, providing precise seizure control. The trial, conducted at Xuanwu Hospital of Capital Medical University, involved three men aged 28 to 37 with drug-resistant epilepsy and hippocampal sclerosis. By injecting a viral vector containing the hM4D gene into the hippocampal lesion areas, the researchers were able to activate the artificial receptor when needed, preventing seizures.

Follow-up results after two months showed an impressive average reduction of 92.6% in seizure frequency, with one patient experiencing no seizures and the other two having zero seizures. While two of the three patients experienced no further seizures during the eight-month follow-up, the third had two breakthrough seizures that were promptly controlled upon resuming clozapine treatment.

All adverse events were mild or moderate. The researchers, led by Zhao Guoguang, president of Xuanwu Hospital and director of the National Centre for Neurological Diseases, emphasize that these findings represent a proof of concept for chemogenetic neuromodulation in drug-resistant epilepsy and call for further evaluation in larger studies.